QCT Collaborates with Samsung and Intel to Lead Transition to PCIe Gen5 with Next-Generation Servers and SSDs
26.7.2022 06:51:00 EEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, today announced the world’s first validation of Samsung PM1743 PCIe Gen5 SSDs in their new all-flash NVMe™ servers powered by 4th Gen Intel® Xeon® Scalable processors. 4th Gen Intel Xeon Scalable processors will deliver substantial compute performance across traditional data center usages with unique purpose-built workload optimizations for today’s edge to cloud models. These technology updates in QCT’s growing line of QuantaGrid servers add additional performance for Samsung’s high-bandwidth flash storage due to the 4th Gen Intel Xeon Scalable processors support of leading industry standard technologies such as DDR5, Intel® Optane™ persistent memory, and PCIe Gen5. Furthermore, these unique solutions provide flexibility for modern data center needs ranging from low latency applications to data processing, and hyper-converged infrastructures (HCI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005386/en/
SVP & GM of QCT, Mike Yang (left) and EVP of Samsung Electronics, Yongcheol Bae (right) announce collaboration to pioneer PCIe Gen5 SSD systems (Photo: Business Wire)
To accommodate the rapidly increasing performance requirements of data centers, PCIe Gen5 doubles IOPS per watt and throughput compared to the previous generation. Samsung’s PM1743 SSD for enterprise servers integrates the PCIe Gen5 interface with Samsung’s advanced sixth-generation V-NAND to deliver 30% enhanced power efficiency than the previous generation, resulting in lower server operating costs and increasing scalability for virtualized environments like HCI and software-defined storage.
With the evolution of data centers to the rapid growth of data and proliferation of applications that demand high performance, QCT’s upcoming QuantaGrid series offer flexibility for scaling out with Samsung’s new storage innovation. The QuantaGrid D54X-1U and D54Q-2U are designed for dual 4th Gen Intel Xeon Scalable processors with 32 DDR5 DIMM slots and support for Intel Optane persistent memory, which provides affordable memory capacity expansion and support for data persistence. The two servers mainly differ in storage capacity and number of expansion slots that will be further revealed with the release of 4th Gen Intel Xeon Scalable processors.
“QCT worked closely with Samsung to test and be among the first to validate Samsung’s PM1743 PCIe Gen5 SSDs on our Intel powered systems,” said Mike Yang, President of QCT. “Together with Samsung, and Intel, our technology leadership will continue to drive new applications as we accelerate the growth of the server market and deliver unparalleled performance advantages for IOPS-intensive applications.”
"Samsung has been working closely with QCT and Intel to show PCIe Gen5 PM1743 SSDs provide optimized performance for all-flash NVMe workloads in their QuantaGrid 1U and 2U systems," said Yongcheol Bae, Executive Vice President of the Memory Application Engineering Team at Samsung Electronics. “Collectively, with the introduction of our PCIe Gen5 SSD, Intel’s 4th Gen Xeon Scalable processors, and QCT’s QuantaGrid server line we will further solidify our technological leadership in the enterprise server market.”
“Our goal is to deliver industry leadership to accelerate data center performance and user experiences with our upcoming 4th Gen Intel Xeon Scalable processors,” said Zane Ball, Intel Corporate Vice President and General Manager of Data Platforms Engineering and Architecture. “The collaboration with QCT and Samsung signifies Intel’s commitment to providing our customers with a multitude of ways to enhance their applications with high-speed NVMe SSDs that enable deployments from edge to cloud.”
Follow QCT on Facebook and Twitter to receive their latest news and announcements.
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About QCT
QCT is a global datacenter solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. www.QCT.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005386/en/
Contact information
Janet Chang
Janet.chang@quantatw.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 13:45:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we see an opportunity to bring decision-makers closer to insight and reduce the manual effort between data and action," said Rishi Padhi, SVP and Chief Digital and Information
Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 13:18:00 EEST | Press release
Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified protocol and statistical analysis plan. Within this clinically high-risk population, myStage Dx identified two groups with markedly different long-term outcomes. The Low Risk group comprised 23.5% of patie
Zoom Advances Its AI Strategy With a New Unified Context Layer That Helps Turn Meeting Conversations Into Completed Work22.10.2026 13:13:00 EEST | Press release
Today at its annual Zoomtopia customer conference, Zoom Communications, Inc. (NASDAQ: ZM), a leading AI-first platform for human connection, introduced a new Unified Context Layer and several new products with AI-powered capabilities. The new offerings are designed to help businesses transform rich meeting context into meaningful deliverables that help accelerate work outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021498160/en/ Business conversations drive critical decisions and build customer history every day. A customer interaction might start in a meeting, continue by phone, and carry on in chat threads. But when that context is scattered across applications, people, and AI agents lose the thread, and teams spend significant time piecing together what happened, when it happened, and what they should do about it. Zoom’s new Unified Context Layer helps close that gap by linking conversation history with releva
TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 13:01:00 EEST | Press release
TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA AI models and tools to further enhance capabilities across advanced reasoning, autonomous analysis and video intelligence. The integration allows TACTICAAI to draw on NVIDIA’s AI ecosystem while maintaini
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 13:01:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom